- Home
- SIGA vs MSLE Comparison
SIGA vs MSLE Comparison
Compare SIGA & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SIGA | MSLE |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 186.9M |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SIGA | MSLE |
|---|---|---|
| Price | $3.15 | $7.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.17 |
| AVG Volume (30 Days) | ★ 590.9K | 66.7K |
| Earning Date | 11-05-2026 | 11-15-2026 |
| Dividend Yield | ★ 18.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $170.70 | N/A |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $5.44 |
| 52 Week High | $8.54 | $13.39 |
Technical Indicators
Market Signals| Indicator | SIGA | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 27.67 |
| Support Level | $2.87 | $5.52 |
| Resistance Level | $3.32 | $10.58 |
| Average True Range (ATR) | 0.14 | 0.59 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 17.97 | 5.91 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.